Oric Pharmaceuticals Inc
$ 10.53
1.25%
14 Apr - close price
- Market Cap 1,164,877,000 USD
- Current Price $ 10.53
- High / Low $ 10.85 / 10.39
- Stock P/E N/A
- Book Value 3.90
- EPS -1.47
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.41 %
- 52 Week High 14.93
- 52 Week Low 4.52
About
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San Francisco, California.
Analyst Target Price
$21.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-24 | 2025-11-13 | 2025-08-12 | 2025-05-05 | 2025-03-10 | 2024-11-04 | 2024-08-12 | 2024-05-06 | 2024-03-11 | 2023-11-06 | 2023-08-10 | 2023-05-08 |
| Reported EPS | -0.3 | -0.33 | -0.47 | -0.42 | -0.51 | -0.49 | -0.45 | -0.37 | -0.49 | -0.44 | -0.5 | -0.53 |
| Estimated EPS | -0.3669 | -0.4 | -0.44 | -0.44 | -0.5084 | -0.4717 | -0.41 | -0.44 | -0.49 | -0.46 | -0.57 | -0.54 |
| Surprise | 0.0669 | 0.07 | -0.03 | 0.02 | -0.0016 | -0.0183 | -0.04 | 0.07 | 0 | 0.02 | 0.07 | 0.01 |
| Surprise Percentage | 18.2339% | 17.5% | -6.8182% | 4.5455% | -0.3147% | -3.8796% | -9.7561% | 15.9091% | 0% | 4.3478% | 12.2807% | 1.8519% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ORIC
2026-04-12 10:39:58
ORIC Pharmaceuticals (ORIC) saw its stock rise by 14.2% after advancing its PRC2 inhibitor, rinzimetostat (ORIC-944), combined with darolutamide, into a global Phase 3 registrational trial for metastatic castration-resistant prostate cancer. The company selected a 400 mg once-daily regimen based on encouraging Phase 1b data, targeting a market estimated at over US$7.00 billion worldwide. This move solidifies rinzimetostat plus darolutamide as ORIC's central asset, emphasizing the importance of trial execution and regulatory dialogue for its investment narrative.
2026-04-11 20:10:15
This article provides a detailed analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), highlighting a strong risk-reward setup with a potential 31.7% gain. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and key findings regarding near-term sentiment and long-term strength. The report emphasizes the role of AI models in optimizing position sizing and minimizing drawdown risk for institutional trading strategies.
2026-04-10 18:40:14
This article analyzes ORIC Pharmaceuticals' cash burn rate in relation to its cash reserves and market capitalization. It concludes that despite a significant cash burn, the company has sufficient cash to sustain operations for over three years, minimizing immediate concerns for investors.
2026-04-09 17:38:39
Shares of Oric Pharmaceuticals (NASDAQ:ORIC) rose 6.5% despite a broader market decline, reflecting investor confidence in its cancer therapy pipeline. Analysts have maintained buy ratings with price targets between $15 and $25, citing the company's focus on overcoming drug resistance with its lead candidate ORIC-101. The stock's performance highlights its potential in the competitive oncology landscape, with investors closely watching its progress in Phase 1/2 trials.
2026-04-07 17:09:56
ORIC Pharmaceuticals (ORIC) is undergoing a valuation review after advancing its prostate cancer drug rinzimetostat to a Phase 3 trial. Despite recent share price volatility, the company shows strong long-term momentum. Simply Wall St's discounted cash flow model suggests ORIC is undervalued at $43.32 against a current trading price of $8.89, though its price-to-book ratio offers a more cautious perspective.
2026-04-07 06:11:19
Oric Pharmaceuticals (NASDAQ:ORIC) has received a "Moderate Buy" consensus rating from fourteen brokerages, with an average 12-month price target of $19.90. This comes despite a significant insider sale by CFO Dominic Piscitelli and the company's current negative P/E ratio. Institutional ownership is high at 95.05%, with several major firms increasing their stakes.
